Ocular Inflammation And Pain Pipeline Analysis & Clinical Trials, 2025, Delveinsight Formosa Pharmaceuticals, Sun Pharma Advanced Research Company Limited, Sun Pharma Global FZE, A.T. Resolve SARL

(MENAFN- GetNews)


"Ocular inflammation and pain Pipeline Analysis & Clinical Trials"DelveInsight's,“Ocular Inflammation and Pain – Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Ocular Inflammation and Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight's Ocular inflammation and pain Pipeline Clinical Trials Analysis Report provides deep insights to support strategic decision-making for Ocular inflammation and pain pipeline expansion, competitive positioning, and partnership identification in the rare neurodegenerative disease space.

Ocular inflammation and pain Overview:

Inflammation is the body's natural reaction to injury, infection, or irritation. It can also occur in response to harmless substances, such as dust, pollen, or grass, triggering an allergic reaction. Additionally, the immune system may mistakenly attack the body's own tissues, leading to an autoimmune response. Ocular inflammation can arise from infections, allergies, autoimmune conditions, irritation, or trauma affecting the eye or eyelid. Common symptoms include blurred vision, pain, redness, swelling, tearing, and warmth in the eyes, eyelids, or surrounding areas. This condition is frequently observed in patients with systemic inflammatory disorders such as rheumatoid arthritis, lupus, sarcoidosis, Wegener's granulomatosis, Sjögren's syndrome, and others.

Download our report @

"Ocular inflammation and pain Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Ocular inflammation and pain Therapeutics Market.

Key Takeaways from the Ocular inflammation and pain Pipeline Report

• DelveInsight's Ocular Inflammation and Pain Pipeline Report highlights a dynamic landscape, with over 5 companies developing more than 5 therapeutic candidates for the treatment of ocular inflammation and pain.

• A corticosteroid ophthalmic suspension, approved on March 4, 2024, is indicated for post-operative inflammation and pain following eye surgery. Clinical studies reported ocular adverse reactions in ≥1% of patients, including eye inflammation (2%), corneal edema (2%), anterior chamber inflammation (2%), cystoid macular edema (2%), elevated intraocular pressure (1%), photophobia (1%), and vitreous detachment (1%).

• MIEBO, approved on May 18, 2023, is a first-in-class therapy for the signs and symptoms of dry eye disease (DED), a multifactorial, age-related, chronic progressive disorder of the ocular surface. MIEBO is specifically indicated for alleviating both the signs and symptoms of DED.

• Leading companies in this space include Formosa Pharmaceuticals, Inc., Sun Pharma Advanced Research Company Limited, Sun Pharma Global FZE, A.T. Resolve SARL, Tarsius Pharma, SALVAT, and others, all working to expand treatment options. Promising pipeline candidates include APP13007 and additional therapies aimed at improving the ocular inflammation and pain treatment landscape.

Ocular inflammation and pain Pipeline Analysis

The Ocular inflammation and pain pipeline insights report 2025, provides insights into:

• Provides comprehensive insights into key companies developing therapies in the Ocular inflammation and pain Market.

• Categorizes Ocular inflammation and pain therapeutic companies by development stage: early, mid, and late-stage.

• Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

• Reviews emerging Ocular inflammation and pain drugs under development based on:

  • Stage of development

  • Ocular inflammation and pain Route of administration

  • Target receptor

  • Monotherapy vs. combination therapy

  • Ocular inflammation and pain Mechanism of action

  • Molecular type

• Offers detailed analysis of:

  • Company-to-company and company-academia collaborations

  • Ocular inflammation and pain Licensing agreements

  • Funding and investment activities supporting future Ocular inflammation and pain market advancement.

Request for a sample report @

Ocular inflammation and pain Emerging Drugs

• APP13007: Formosa pharmaceuticals

APP13007, developed using our proprietary APNT formulation platform, is an aqueous ophthalmic nanosuspension designed to manage post-operative pain and inflammatory eye conditions. Its active ingredient is a potent corticosteroid with over 30 years of proven efficacy and safety in dermatological applications across the U.S., Europe, and Japan. APP13007 represents the first ophthalmic application of this well-established compound. Following the completion of Phase II studies in 2020, it advanced to Phase III clinical trials in the U.S. in March 2022.

Ocular inflammation and pain Companies

More than five key companies are developing therapies for ocular inflammation and pain, with Formosa Pharmaceuticals leading the field with candidates currently in Phase III trials, the most advanced stage of development.

DelveInsight's report covers around 5+ products under different phases of Ocular inflammation and pain clinical trials like

• Ocular inflammation and pain Late stage Therapies (Phase III)

• Ocular inflammation and pain Mid-stage Therapies (Phase II)

• Ocular inflammation and pain Early-stage Therapies (Phase I)

• Ocular inflammation and pain Pre-clinical and Ocular inflammation and pain Discovery stage Therapies

• Ocular inflammation and pain Discontinued & Inactive Therapies

Ocular inflammation and pain pipeline report provides the Ocular inflammation and pain therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Ocular inflammation and pain Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Ocular inflammation and pain Therapies and Key Ocular inflammation and pain Companies: Ocular inflammation and pain Clinical Trials and recent advancements

Ocular inflammation and pain Pipeline Therapeutic Assessment

. Ocular inflammation and pain Assessment by Product Type

. Ocular inflammation and pain By Stage

. Ocular inflammation and pain Assessment by Route of Administration

. Ocular inflammation and pain Assessment by Molecule Type

Ocular inflammation and pain Report Section Includes:

• Ocular inflammation and pain competitive landscape clinical trials

• Ocular inflammation and pain emerging drugs analysis

• Ocular inflammation and pain investigational drugs report

• Ocular inflammation and pain clinical trial trends analysis

• Ocular inflammation and pain pipeline benchmarking report

• Ocular inflammation and pain drug pipeline competitive intelligence

• Ocular inflammation and pain competitive landscape

Major trends shaping the clinical trial and competitive landscape for Ocular inflammation and pain:

• Shift Toward Novel and Targeted Therapies: Increased development of corticosteroids, biologics, antisense oligonucleotides, and regenerative therapies to treat underlying inflammation rather than just symptoms.

• Expansion of Clinical Trials: Growth in early- and mid-stage trials, exploring multiple mechanisms, formulations, and combination therapies.

• Regulatory Support: Orphan Drug, Fast Track, and RMAT designations facilitating expedited development for rare or severe ocular conditions.

• Strategic Collaborations: Partnerships among biotech, pharmaceutical companies, and academic institutions to accelerate R&D and share technological expertise.

• Innovation in Drug Delivery and Formulation: Focus on nanosuspensions, topical applications, sustained-release formulations, and ocular implants to improve efficacy and patient compliance.

• Emerging Biomarkers and Patient-Centric Endpoints: Incorporation of clinical and imaging biomarkers, patient-reported outcomes, and vision-related quality-of-life measures to enhance trial precision and relevance.

• Competitive Differentiation: Companies distinguishing pipelines by mechanism of action, route of administration, molecular type, and stage of development.

• Integration of Real-World Evidence: Use of real-world data to support regulatory approval, reimbursement, and post-market monitoring.

Download Ocular inflammation and pain Sample report to know in detail about the Ocular inflammation and pain treatment market @ Ocular inflammation and pain Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Ocular inflammation and pain Current Treatment Patterns

4. Ocular inflammation and pain - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Ocular inflammation and pain Late-Stage Products (Phase-III)

7. Ocular inflammation and pain Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Ocular inflammation and pain Discontinued Products

13. Ocular inflammation and pain Product Profiles

14. Ocular inflammation and pain Key Companies

15. Ocular inflammation and pain Key Products

16. Dormant and Discontinued Products

17. Ocular inflammation and pain Unmet Needs

18. Ocular inflammation and pain Future Perspectives

19. Ocular inflammation and pain Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Ocular inflammation and pain Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

MENAFN08092025003238003268ID1110033998